More than 1 million people dies worldwide due to lung cancer which is the first most incident cancer in males and the third in females. Only early diagnosis makes possible to achieve long-lasting remission or even cure the disease. Unfortunately, no tumour marker to achieve this goal has been identified, yet. One of putative lung cancer markers is free circulating tumor DNA. Its concentration seems to be related to cancer burden. Moreover, it can be subjected to mutational status analysis allowing for introduction of targeted treatment. This led to the idea of liquid biopsy which can substitute for a standard biopsy not feasible in certain clinical circumstances. Assessment of cell free tumour DNA can also inform about progression/recurrence of cancer and may have a prognostic value. Therefore, the aim of this article is to review on free circulating DNA as a potential marker in lung cancer.
Biomarkers of malignancy
Incidence of malignant tumours worldwide is growing, making them a serious epidemiological hazard. The data obtained from the National Cancer Registry over the last three decades confirm that the incidence of malignant tumours in Poland has increased twice (from 64 700 in 1980 to above 140 500 cases in 2010); in 2013, this number reached almost 156 500 cases. Lung cancer occupies the first place in males (18.7%) and the third place in females (8.8%) as the most frequently diagnosed malignancy [1] . Early detection allows to implement an optimal treatment on time, and consequently to obtain a long overall or progression-free survival. To this end, screening diagnostic tests have been pursued, and recently a low-dose CT scan has been proposed as a screening tool for lung cancer in a population at risk, i.e. heavy smokers [2, 3] .
Apart from imaging studies, a different approach to screening have been based on biomarkers of cancer, which ideally, should be a sensitive (but also relatively specific) substance present in body fluids, e.g. blood, urine or sputum, definitely easier to collect than cancer tissue [4] . Moreover, despite diagnostic potential, biomarkers can also exhibit predictive (of a response to treatment) or prognostic (overall survival or progression-free survival) attributes [5] .
From the historic perspective, the first cancer biomarker was an immunoglobulin present in the urine of patients with multiple myeloma, which was identified as early as in 1848 [6] . The twentieth century witnessed discoveries of numerous hormones, proteins and enzymes, marking patients with a particular malignancy. In the 1960s, an alpha-fetoprotein and CEA (carcinoembryonic antigen) were identified in blood. Subsequently, [5] . Technological progress which took place at the end of the twentieth century contributed to the development of molecular diagnostics. In effect, circulating cell-free tumour DNA (ct-DNA) was identified in blood and proposed as a plausible biomarker of malignancy [7, 8] .
Cell-free circulating DNA
Circulating blood contains natural cell-free DNA (cf-DNA) that comes mostly from apoptotic cells. Rapid turnover of tumour cells during growth, metastatic disease or cancer therapy, results in a release of a number of molecular biomarkers into the peripheral blood. One of these is ct-DNA that differs from its physiological counterpart by more variable helix length and by the presence of specific mutations. Apoptotic cf-DNA length is a multiple of 180-200 base pairs from nucleosome derived fragments while ct-DNA reveals variable and usually shorter or longer strand length with fragments over 10kb considered characteristic of necrosis [9, 10] . Obviously, in subjects with no malignancy, only physiological cf-DNA is found in blood. In case of cancer, concentration of its neoplastic counterpart is highly variable and may constitute from less than 1 up to 90% of total cf-DNA, which probably depends on tumour type and stage [11, 12] . For instance, ct-DNA was present in almost all patients with colorectal or pancreatic carcinoma, while in minority of cases with prostate or renal cell carcinoma [13] . Theoretically, to detect circulating ct-DNA in blood, the cancer must consist of at least 50 million cells, which is a small number, considering the fact that a tumour 7-10 mm in diameter that can be detected by imaging studies consists of at least 1 billion cells [5] . In effect, detecting ct-DNA may be more sensitive than other diagnostic modalities and may plausibly allow for early diagnosis.
Moreover, ct-DNA may be subjected to qualitative analysis of a mutational status of a tumour [12, 14] . Some of the mutations detectable in ct -DNA are believed to be responsible for malignant transformation, leading to uncontrollable growth and cell divisions, hence, they are called driver or primary mutations and, of note, they can be a target of specific drugs, e.g. inhibitors of receptor kinases. Other mutations are new mutations occurring in the course of cancer (secondary ones) which may be responsible for the emergence of resistance to cancer therapy [15] .
Cell-free circulating DNA as a source of material to assess mutational status of the tumour
The assessment of mutational status of the tumour is paramount for introduction of specific treatment, e.g. inhibitors of receptor kinases. Still, an analysis of material from biopsy of a tumour or metastases is considered the gold standard. Nevertheless, this standard has been lately challenged by some discoveries implying heterogeneity of mutational status within tumour or between tumour and metastases. For instance, we have recently found that the material from separate parts of the tumour specimen harboured different KRAS mutation at codon 12, or some parts of the tumour harboured a wild gene while the others a mutated one [16] . Therefore, finding no mutation on a standard biopsy may not always be a true negative result, meaning the lack of sensitivity, and in effect low negative predictive value. So, the analysis of ct-DNA may plausibly be a better source of material as it presumably derives from all parts of the tumour, with cells harbouring different mutations or a wild gene simultaneously. Therefore, an isolation of ct-D-NA from a small amount of blood for analysis of mutations was called a "liquid biopsy" [12] .
What is more important, in some patients, it is not feasible to obtain a suitable tissue sample for assessment of mutations relevant to introduction of a second line treatment. This may be due to insufficient amount of the biopsy material or safety, ethical or technical issues entailed to re-biopsy. Detection of ct-DNA in the peripheral blood might be an alternative procedure. A small sample of blood contains enough cf-DNA (including ct-DNA), to be used for rapid genotyping in order to detect mutations. An analysis of ct-DNA could be repeated any time as needed and should cause neglectable discomfort to patients [5, 17] . Moreover, as a half time of ct-DNA is only about 2 hours, it can reflect changing mutational status of a tumour [12] . Genetic material obtained in this way is biologically rich enough to enable detections of mutations within ct-DNA and its www.journals.viamedica.pl quantitative evaluation. For instance, Sacher et al. found that analysis of common KRAS and EGFR mutations in ct-DNA among NSCLC patients revealed high positive predictive value potentially informing an optimal treatment [18] . Further, recently published meta-analysis showed lower survival in NSCLC patients with KRAS mutation detected in ct-DNA [19] . Another approach to ct-DNA analysis was to look for methylation of promoters of tumour suppressor genes. Disappointingly, methylation analysis of various promotors of genes implicated in NSCLC pathogenesis (e.g. p16, APC, RARb) was plagued by low sensitivity [20] .
Finally, regulatory bodies in Europe and the USA have recently approved some diagnostic tests detecting EGFR receptor mutations in ct-DNA to inform specific treatment in case no NSCLC tissue can be harvested directly from the tumour or metastases [21] [22] [23] [24] . Nevertheless, the problem highlighted by the ASSESS study was too low sensitivity of only about 50% leading to many false negative results, thus leaving many patients harbouring this driver mutation without optimal treatment [25] .
Concentration of cell-free circulating DNA as a predictive biomarker
The idea that the heavier tumour burden is reflected by the higher concentration of ct-DNA and by this means it can be a predictor of survival is quite attractive. However, the published data on the value of a ct-DNA as a predictor of survival in solid tumours are somewhat contradictory. In one of the first studies, Gautschi et al. found that elevated concentration of ct-DNA correlated with poor survival and tumour progression after chemotherapy [26] . Likewise, Sozzi et al. [27] reported overall high median ct-DNA in patients relapsing in the course of NSCLC, but clinical usefulness of this finding was weakened by some relapsing patients with low level of ct-DNA, i.e. false negatives. Nygaard et al. [28] conducted a study on a small group of 53 patients and observed significantly shorter overall survival and progression-free survival in a subgroup of patients with the upper highest quartile of ct-DNA concentration. Similar results were obtained by Tissot et al. [29] , namely ct-DNA at the highest tertile of concentration spectrum was associated with shorter overall survival and progression-free survival. Extracellular DNA can also be detected in other easily obtainable body fluids, e.g. exhaled breath condensate. In NSCLC patients with confirmed KRAS mutation at codon 12 after a tumour resection, a ratio of mutated to wild type KRAS in exhaled breath condensate decreased over one month of observation [30] . This phenomenon may possibly be used in monitoring patients for completeness of resection or recurrence of a tumour. In line with this assumption are results published by Kumar et al. [31] , namely high basal ct-DNA concentration, and smaller decreases of its level observed in the course of chemotherapy were related to worse outcome.
Quite the contrary, a study published by Li et al. [32] on a group of 103 patients showed no relation between concentrations of ct-DNA before any systemic treatment and the survival. Also ct -DNA changes did not correlate with the RECIST (Response Evaluation Criteria in Solid Tumours) criteria of response to treatment. Similarly, ct -DNA concentration did not predict survival in patients treated with tyrosine kinase inhibitors [33] . Nevertheless, a meta-analysis of 16 studies showed that a high ct-DNA concentration increased the risk of death of lung cancer patients but did not affect progression-free survival [34] .
Concentration of cell-free circulating DNA as a diagnostic biomarker
Another way to assess clinical value of ct -DNA is quantitative analysis with presumption that in malignancy, higher concentration can have discriminatory value and allow for an early, non-invasive cancer detection. Szpechcinski et al. [35] found that ct-DNA level was higher in NSCLC patients compared to healthy controls and subjects suffering from chronic inflammatory lung diseases. Similarly, in another work by this group, ct-DNA concentration was markedly elevated in NSCLC vs. patients with benign lung nodules [36] . Nevertheless, at the discriminatory concentration levels proposed by the authors calculated predictive values were below 90%, not allowing for ruling in or out NSCL diagnosis. Further, Leng et al. [37] showed that in NSCLC patients higher and differential ct-DNA concentrations were observed compared to tuberculosis group. Moreover, the authors emphasised a greater sensitivity of ct-DNA compared to traditional biomarkers, such as CA125, NSE and CEA. Unfortunately, calculating predictive values from data provided by the authors yields mediocre results, not fully supporting the overoptimistic conclusions.
Conclusions
A small sample of blood is sufficient to determine genetic changes in the tumour by analysis www.journals.viamedica.pl of ct-DNA. Determination of new mutations and assessment of concentration of ct-DNA seem to increasingly have place in non-invasive cancer screening. Nevertheless, the lack of standardisation of the methods used to assess ct-DNA is a major drawback and hinders wider clinical application. Therefore, standardisation of research on ct-DNA regarding its reference plasma concentration and in effect cut-off values for patients with NSCLC is of paramount importance. Moreover, clinical evaluation on larger groups of patients in prospective studies in respect to NSCLC diagnosis and prognosis may lead to wide implementation of liquid biopsy. Perhaps in the near future, this can be an robust alternative to a traditional tumour biopsy.
